Daniel Metzen Selected Research

Infarction (Infarctions)

1/2023

Revealing concealed cardioprotection by platelet Mfsd2b-released S1P in human and murine myocardial infarction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel Metzen Research Topics

Disease

2	Hemorrhage 01/2023 - 01/2021
2	Non-ST Elevated Myocardial Infarction 01/2022 - 01/2020
1	Cardiogenic Shock 12/2023
1	Atrial Fibrillation 01/2023
1	Ischemia 01/2023
1	Infarction (Infarctions) 01/2023
1	ST Elevation Myocardial Infarction 01/2023
1	Starvation 01/2022
1	Transient Ischemic Attack 11/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2021
1	Stroke (Strokes) 11/2021
1	Myocardial Infarction 11/2021
1	Diabetes Mellitus 01/2021
1	Autistic Disorder (Autism) 06/2020
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2020

Drug/Important Bio-Agent (IBA)

2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 11/2021 - 01/2020
1	Heparin (Liquaemin)FDA LinkGeneric 12/2023
1	Vitamin K FDA Link 01/2023
1	Sphingosine-1-Phosphate ReceptorsIBA 01/2023
1	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 01/2023
1	RivaroxabanIBA 01/2023
1	apixabanIBA 01/2023
1	CarbonIBA 01/2022
1	Clopidogrel (Plavix)FDA Link 01/2022
1	Dipyrone (Metamizole)IBA 11/2021
1	NexusIBA 06/2020

Therapy/Procedure

1	Percutaneous Coronary Intervention 01/2021
1	Secondary Prevention 01/2020